
News|Videos|June 24, 2025
ARCHES: 5-Year Follow-up Overall Survival (OS) Analysis of Enzalutamide (ENZA) Plus Androgen-Deprivation Therapy (ADT) in Patients (pts) With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Author(s)Andrew J. Armstrong, MD
Andrew J. Armstrong, MD, ScM, FACP, presented 5-year follow-up data from the ARCHES trial showing that enzalutamide plus androgen-deprivation therapy significantly prolonged overall survival versus placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer, with consistent benefit across subgroups and no new safety signals.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
4
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
5



































